Chai Discovery
AI overview
Sign in and the AI will write an overview from our coverage.
Headlines · 4
- Who Is Setting the Price for AI4S?
SVTR statistics cited in a 潮涌AI article, authorized for publication by 36Kr, cover 118 confirmed financing rounds for 175 AI4S companies from September 2025 to September 2026, totaling about $7.5 billion. Isomorphic Labs accounted for $2.1 billion, or 28% of the total, while 13 companies with individual rounds above $100 million captured 73%. The analysis proposes four valuation layers—pipeline, platform, tools and capital—linked respectively to pharmaceutical R&D budgets, computing and laboratory infrastructure costs, software spending and prospective exit buyers. The framework is the analysis's own interpretation, and several reported high-value financings and valuations were still under negotiation.
虎嗅 AI · 🔥 0 - Overseas AI4S Top 30 highlights layered validation standards
Tide AI selected 30 representative overseas AI for Science companies across materials and chemistry, AI drug discovery, and other scientific intelligence, with 10 in each group. The survey distinguishes benchmark leadership, clinical-stage assets, software revenue and renewals, and conditional partnership value as separate evidence. It also notes that the order is neither an investment rating nor a market ranking, and that company-reported benchmarks, partnership terms, and milestones do not by themselves establish realized revenue, clinical success, or reproducibility.
36氪 人工智能 · 🔥 0 - Insilico Medicine reports 2026 first-half profitability and AI pipeline progress
Insilico Medicine announced profitability in the first half of 2026, according to a 36Kr report. The report says 35 pipeline assets developed with its generative-AI platform, Pharma.AI, reached preclinical candidate compound status, while disclosed business-development cooperation involving its AI platform and pipeline totaled US$11 billion. In the interview, co-CEO Ren Feng said 70%–80% of the company’s code is written by AI and that AI now has substantial weight in drug-development decisions. He also said automated laboratories still require manual validation and calibration before experiments can be run, and that current technology is insufficient for a fully autonomous research loop.
36氪 人工智能 · 🔥 0 - AI drug design is flooding Chinese labs with wet-lab work
Anthropic's Claude designed 1,320 binding proteins against a dozen targets, which Adaptyv Bio and Twist synthesized and tested; 354 were confirmed to bind, a hit rate near 30% versus the traditional 10%–15%. The article argues that as AI pushes the marginal cost of molecular design toward zero, the first orders flow to lab-service providers: GenScript's AIDD revenue doubled year over year in H1 with gross margins about 20 points above its traditional protein-expression business, while XtalPi posted 803 million yuan in 2025 revenue, tripled and its first full-year profit. Meanwhile Washington is trying to pull early-stage R&D and clinical capacity back onshore via HHS's TrialBlazer plan and the BIOSECURE Act.
MIT科技评论中文 · 🔥 0
Experience and discussion from the community
Share my Chai Discovery experienceAsk about Chai Discovery
Nobody has shared their experience with Chai Discovery yet.